VALN Earnings

VALN reported its earnings on 2025-11-20, showcasing a revenue of 29.00M against an estimate of 39.00M, resulting in a -24.79% surprise. The EPS was 0, surpassing the expected -0.3 by 0% . The stock experienced a -1.95% price change on the earnings day and a 0.46% change over the next five days, reflecting market reactions to the results.

Following VALN's earnings announcement on 2025-11-20, the stock price moved by -1.95% on the day of the release. Over the subsequent five days, it saw a 0.46% change. Historically, VALN's stock price tends to shift by an average of -3.68% in the 10 days leading up to earnings and -0.83% in the 10 days following, providing insight into potential market.

For , analysts estimate VALN’s annual revenue to reach undefined, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -4.48% and EPS estimates Revise Downward by -8.87% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between VALN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -4.48%, while EPS estimates moved Revise Downward by -8.87% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, VALN's stock price typically moves by -3.68% in the 10 days before its earnings and -0.83% in the 10 days after. For the upcoming earnings, analysts expect an EPS of undefined and revenue of undefined.

The earnings call revealed mixed financial performance, with a significant operating loss and negative EBITDA largely due to the absence of last year's PRV sale. While there were improvements in gross margins, the temporary U.S. license suspension for IXCHIQ and unclear FDA timelines add uncertainty. The Q&A highlighted management's lack of specific guidance on key issues like IXCHIQ's suspension and DUKORAL's growth in Germany, leading to a negative sentiment. The absence of clear guidance and the mixed financial results suggest a likely negative stock price reaction.